Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03054194 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730
A Phase 1 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03054194 is a Phase 1 study that has completed, run by Eisai. The registered enrollment target is 8 participants.
The verdict
NCT03054194, a Phase 1 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Study E2730-A001-001 is a first-in-human, sequential ascending single dose, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics (PK) of a single oral dose of E2730 in healthy participants.
Interventions
- DRUG Placebo
- DRUG E2730
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2017-01-31 |
| Est. Completion | 2017-03-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03054194
The ClinicalTrials.gov registry entry for NCT03054194 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03054194 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03054194 about?
NCT03054194 is a clinical study titled "Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730". Study E2730-A001-001 is a first-in-human, sequential ascending single dose, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics (PK) of a single oral dose of E2730 in healthy participants.
What is the current status of trial NCT03054194?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2017-01-31. Estimated completion is 2017-03-02.
What interventions are being tested in trial NCT03054194?
The interventions under investigation include: Placebo (DRUG), E2730 (DRUG).
Who is sponsoring clinical trial NCT03054194?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.